Ropes & Gray advised LianBio in a licensing agreement with Janssen Pharmaceuticals, a Johnson & Johnson company, in which LianBio has assigned to Janssen Lian’s exclusive rights to develop and commercialize a first-in class investigational radioenhancer activated by radiotherapy, NBTXR3, in China, South Korea, Singapore and Thailand. The transaction was announced on December 26.

Under the agreement, LianBio will receive a one-time payment of $25 million and is eligible to receive a sales milestone payment of $5 million.

In 2021, Ropes & Gray represented LianBio in in-licensing the original rights to NBTXR3 from Nanobiotix.

NBTXR3 is being evaluated in solid cancer tumors including locally advanced head and neck squamous cell carcinoma.

The Ropes & Gray team was led by life sciences licensing partner Hannah England and included emerging companies and venture capital partner Zach Blume, tax partner Elaine Murphy and tax counsel Michael Mendel.

Leave a comment

Your email address will not be published. Required fields are marked *